Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of budesonide to poractant alfa to prevent bronchopulmonary
dysplasia in preterm infants with respiratory distress syndrome. Half of the participants
will receive budesonide and poractant alfa in combination, and the other half will receive
poractant alfa with saline.